FDA panel recommends reclassification of tumour markers
This article was originally published in Clinica
Executive Summary
The FDA's Immunology Devices Advisory Panel voted unanimously on December 1st to recommend that tumour marker assays be reclassified from Class III to Class II devices. The reclassification pertains only to assays used to monitor the recurrence of tumours or for treatment response and not those for diagnosing tumours such as prostate specific antigen assays.
You may also be interested in...
Prestige Expands UK Eye Care Range In Response To Consumer Demand
A “great consumer response” to TheraTears in the UK leads Prestige Consumer Healthcare to add TheraTears 5-in-1 Irritation and Redness eye drops to the range.
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.